Structured evidence table for Prebiotic Gut Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Prebiotic Gut Health Randomized Trial | Background Gut health is closely associated with metabolic homeostasis, and alterations in gut microbiota composition have been linked to inflammation and metabolic disorders. | 2 | Wu CK (2026) | The Effects of a Prebiotic Formula Promoting <i>Akkermansia muciniphila</i> (AKK) on Gut Health: A Single-Centre, Randomised Controlled Trial. |
| Prebiotic Gut Health Randomized Trial | muciniphila in gut-related metabolic pathways, clinical evidence supporting its effects on microbiome regulation and metabolic outcomes remains limited. | 2 | Wu CK (2026) | The Effects of a Prebiotic Formula Promoting <i>Akkermansia muciniphila</i> (AKK) on Gut Health: A Single-Centre, Randomised Controlled Trial. |
| Prebiotic Gut Health Randomized Trial | Gut microbiome analysis further demonstrated selective changes in gut microbiota composition in the AKK formula group, including an increased relative abundance of Bifidobacterium and decreased relative abundances of Proteobacteria , Erysipelotrichia , and Escherichia-Shigella . | 2 | Wu CK (2026) | The Effects of a Prebiotic Formula Promoting <i>Akkermansia muciniphila</i> (AKK) on Gut Health: A Single-Centre, Randomised Controlled Trial. |
| Prebiotic Gut Health Randomized Trial | Prebiotics targeting specific taxa, such as Akkermansia muciniphila , have attracted interest for their potential to modulate gut microbiota composition. | 2 | Wu CK (2026) | The Effects of a Prebiotic Formula Promoting <i>Akkermansia muciniphila</i> (AKK) on Gut Health: A Single-Centre, Randomised Controlled Trial. |
| Prebiotic Gut Health Randomized Trial | Consequently, current management strategies focus on early detection and the control of modifiable risk factors to delay disease progression and reduce associated complications []. | 2 | Di Renzo Tiziana (2026) | Impact of Probiotics, Prebiotics and Synbiotics Supplementation in Chronic Kidney Disease: A Comprehensive Review of Clinical Trials |
| Prebiotic Gut Health Randomized Trial | 13 Increasing evidence highlights the role of the gut microbiota in CKD pathophysiology. | 2 | Di Renzo Tiziana (2026) | Impact of Probiotics, Prebiotics and Synbiotics Supplementation in Chronic Kidney Disease: A Comprehensive Review of Clinical Trials |
| Prebiotic Gut Health Randomized Trial | p N CKD is consistently associated with marked alterations in gut microbiota composition and function. | 2 | Di Renzo Tiziana (2026) | Impact of Probiotics, Prebiotics and Synbiotics Supplementation in Chronic Kidney Disease: A Comprehensive Review of Clinical Trials |
| Prebiotic Gut Health Randomized Trial | 1 2 3 4 5 6 3 7 2 4 5 8 9 10 11 12 Chronic kidney disease (CKD) is a major global health concern affecting more than 10–13% of adults worldwide [,,,,] and is projected to become the fifth leading cause of death by 2040 []. | 2 | Di Renzo Tiziana (2026) | Impact of Probiotics, Prebiotics and Synbiotics Supplementation in Chronic Kidney Disease: A Comprehensive Review of Clinical Trials |
Source documents